CA2514646C - Factor viii polypeptide - Google Patents

Factor viii polypeptide Download PDF

Info

Publication number
CA2514646C
CA2514646C CA2514646A CA2514646A CA2514646C CA 2514646 C CA2514646 C CA 2514646C CA 2514646 A CA2514646 A CA 2514646A CA 2514646 A CA2514646 A CA 2514646A CA 2514646 C CA2514646 C CA 2514646C
Authority
CA
Canada
Prior art keywords
fviii
ser
factor viii
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2514646A
Other languages
English (en)
French (fr)
Other versions
CA2514646A1 (en
Inventor
Hun-Taek Kim
In-Young Song
Jae Won Choi
Jin-Wook Jang
Yong-Kook Kim
Ho Soon Lee
Yung-Jue Bang
Dae-Kee Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Bioscience Co Ltd
Original Assignee
SK Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Chemicals Co Ltd filed Critical SK Chemicals Co Ltd
Publication of CA2514646A1 publication Critical patent/CA2514646A1/en
Application granted granted Critical
Publication of CA2514646C publication Critical patent/CA2514646C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/10Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2514646A 2003-01-28 2003-10-27 Factor viii polypeptide Expired - Lifetime CA2514646C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/353,753 2003-01-28
US10/353,753 US7041635B2 (en) 2003-01-28 2003-01-28 Factor VIII polypeptide
PCT/KR2003/002277 WO2004067566A1 (en) 2003-01-28 2003-10-27 Factor viii polypeptide

Publications (2)

Publication Number Publication Date
CA2514646A1 CA2514646A1 (en) 2004-08-12
CA2514646C true CA2514646C (en) 2013-07-23

Family

ID=32736253

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2514646A Expired - Lifetime CA2514646C (en) 2003-01-28 2003-10-27 Factor viii polypeptide

Country Status (13)

Country Link
US (1) US7041635B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2253645B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100642293B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN100404552C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003274766B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2017C021I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2514646C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK2253645T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2446041T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR17C1024I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00023I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300878I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004067566A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
DE602004026474D1 (de) * 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖peg化顆粒球コロニー刺激因子
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
CA2604299A1 (en) * 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CA2632714A1 (en) 2005-12-07 2007-06-14 Technische Universitaet Muenchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
US20080070251A1 (en) * 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP3112471A1 (en) 2007-02-23 2017-01-04 Sk Chemicals Co., Ltd. Process for producing and purifying factor viii and its derivatives
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
EP2711436A1 (en) * 2007-11-01 2014-03-26 University Of Rochester Recombinant factor VIII having increased stability
US20100286067A1 (en) * 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
EP2288365A4 (en) * 2008-05-16 2012-05-09 Bayer Healthcare Llc TARGETED COOLING FACTORS AND METHOD OF APPLICATION THEREFOR
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011041770A1 (en) 2009-10-02 2011-04-07 The Children's Hospital Of Philadelphia Compositions and methods for enhancing coagulation factor viii function
SG10201907152YA (en) 2009-12-06 2019-09-27 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP3560962A1 (en) 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc. Processable single chain molecules and polypeptides made using same
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
WO2012061689A2 (en) * 2010-11-05 2012-05-10 Ipsen Pharma S.A.S. A new variant of antihemophilic factor viii having increased specific activity
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
PT2729161T (pt) 2011-07-08 2019-04-01 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 viii의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
DK2768521T3 (en) 2011-10-18 2016-10-24 Csl Behring Gmbh Combined use of a sulfated glykosamin glycan and a Hyaluronidase to improve bio-availability of factor VIII
HK1198541A1 (en) * 2011-10-18 2015-05-15 Csl Limited Method for improving the stability of purified factor viii after reconstitution
MY201293A (en) 2012-01-12 2024-02-15 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
RS57936B1 (sr) 2012-01-12 2019-01-31 Bioverativ Therapeutics Inc Smanjenje imunogenosti na faktor viii kod osoba na terapiji faktorom viii
PL3564260T3 (pl) 2012-02-15 2023-03-06 Bioverativ Therapeutics Inc. Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania
EP3549953A1 (en) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors
CN104519897A (zh) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 促凝血化合物
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
KR102329315B1 (ko) 2012-07-11 2021-11-19 바이오버라티브 테라퓨틱스 인크. Xten 및 폰 빌레브란트 인자 단백질과의 viii 인자 복합체 및 이의 용도
EP2877202A4 (en) 2012-07-25 2016-06-01 Biogen Ma Inc BLOOD FACTORY MONITOR TEST AND USES THEREOF
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
LT3889173T (lt) 2013-02-15 2023-10-10 Bioverativ Therapeutics Inc. Optimizuotas viii faktoriaus genas
JP6330026B2 (ja) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド 第viii因子ポリペプチド製剤
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CA2913078A1 (en) 2013-06-28 2014-12-31 Biogen Ma Inc. Thrombin cleavable linker with xten and its uses thereof
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子viii-xten融合物及其用途
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
ES2927475T3 (es) 2014-01-10 2022-11-07 Bioverativ Therapeutics Inc Proteínas quiméricas de factor VIII y usos de las mismas
DK3097118T3 (en) * 2014-01-20 2018-11-05 Octapharma Ag PROCEDURE FOR MANUFACTURING FACTOR VIII WITH AN IMPROVED FVIII: C / FVIII: AG RELATIONSHIP
AU2015214245B2 (en) 2014-02-04 2020-09-10 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
BR112017002090B1 (pt) 2014-08-04 2021-06-01 Csl Limited Composição aquosa de fator viii de coagulação e método de estabilizar uma molécula de fviii
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
JP2018510212A (ja) 2015-03-06 2018-04-12 ツェー・エス・エル・ベーリング・レコンビナント・ファシリティ・アクチエンゲゼルシャフト 向上した半減期を有する改変したフォンヴィレブランド因子
JP6651548B2 (ja) 2015-05-22 2020-02-19 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォン・ヴィルブランド因子を製造するための方法
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ix融合蛋白以及其製備及使用方法
WO2017050820A1 (en) * 2015-09-22 2017-03-30 Novo Nordisk A/S Fviii fusion proteins
TWI777175B (zh) 2015-11-13 2022-09-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體之病毒載體
EA202092049A1 (ru) 2015-11-13 2020-11-10 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
CN116218863A (zh) 2016-02-01 2023-06-06 比奥贝拉蒂治疗公司 优化的因子viii基因
US20230151078A1 (en) 2016-06-24 2023-05-18 Mogam Instiitute For Biomedical Research Recombinant single-chain fviii and chemical conjugate thereof
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
JP6351679B2 (ja) * 2016-09-30 2018-07-04 エスケー ケミカルズ カンパニー リミテッド 第viii因子とその誘導体の製造及び精製方法
CN110381986B (zh) 2016-11-11 2023-08-18 康诺贝林伦瑙有限公司 用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽
TW201828975A (zh) 2016-11-11 2018-08-16 瑞士商Csl貝林重組技能公司 用於治療血友病之截短型類血友病因子(von Willebrand factor)多肽類
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
DK3641800T5 (da) 2017-06-22 2024-08-26 CSL Behring Lengnau AG Modulation af fviii immunogenicitet ved trunkeret vwf
IL322212A (en) 2017-08-09 2025-09-01 Bioverativ Therapeutics Inc Nucleic acid molecules and their uses
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ,エルエルシー 凍結乾燥方法
KR20200118089A (ko) 2018-02-01 2020-10-14 바이오버라티브 테라퓨틱스 인크. 인자 viii을 발현하는 렌티바이러스 벡터의 용도
MX2020010369A (es) 2018-04-04 2020-10-22 Sigilon Therapeutics Inc Particulas implantables y metodos relacionados.
LT3793588T (lt) 2018-05-18 2025-06-25 Bioverativ Therapeutics Inc. Hemofilijos a gydymo būdai
BR112021000695A2 (pt) 2018-07-16 2021-04-20 Baxalta Incorporated métodos para tratar hemofilia a e para monitorar a eficácia da terapia gênica de fator viii de hemofilia a.
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
US20220118063A1 (en) * 2018-09-19 2022-04-21 Cell Machines, Inc. Methods and compositions related to improved factor viii long half-life coagulation complexes
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
AU2020221340A1 (en) 2019-02-15 2021-09-16 Bayer Healthcare Llc Gene editing for hemophilia A with improved Factor VIII expression
WO2020242552A1 (en) 2019-03-14 2020-12-03 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
BR112021015776A2 (pt) * 2019-06-05 2021-11-09 Bayer Healthcare Llc Edição de gene para hemofilia a com expressão de fator viii melhorada
WO2020257462A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
JP2022538357A (ja) 2019-07-04 2022-09-01 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第VIII凝固因子のin vitroでの安定性を向上させるための切断型フォン・ヴィレブランド因子(VWF)
KR20220097891A (ko) 2019-09-30 2022-07-08 바이오버라티브 테라퓨틱스 인크. 렌티바이러스 벡터 제형
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
US20230023826A1 (en) 2019-12-12 2023-01-26 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
JP7681268B2 (ja) * 2020-03-30 2025-05-22 シスメックス株式会社 血液凝固活性の測定方法
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
CN117858895A (zh) 2021-06-14 2024-04-09 武田药品工业株式会社 使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法
JP2024532262A (ja) 2021-08-23 2024-09-05 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第viii因子遺伝子
CN118019758A (zh) 2021-09-30 2024-05-10 比奥维拉迪维治疗股份有限公司 编码免疫原性降低的因子viii多肽的核酸
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於A型血友病之基因療法的編碼表現增加之重組FVlll變異體的病毒載體

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US5399670A (en) * 1992-04-30 1995-03-21 Alpha Therapeutic Corporation Solubilization and stabilization of factor VIII complex
DK1754718T3 (da) 1996-04-24 2011-07-18 Univ Michigan Inaktiveringsresistent faktor VIII
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
WO2002102850A2 (en) 2001-06-15 2002-12-27 Schuh Andre C Gene therapy for hemophilia a

Also Published As

Publication number Publication date
WO2004067566A1 (en) 2004-08-12
HK1150840A1 (en) 2012-01-13
AU2003274766B8 (en) 2009-08-27
DK1587832T3 (en) 2014-02-24
CA2514646A1 (en) 2004-08-12
EP2253645B1 (en) 2016-03-23
AU2003274766A1 (en) 2004-08-23
BE2017C021I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-03-07
FR17C1024I2 (fr) 2019-07-19
NL300878I2 (nl) 2017-11-02
FR17C1024I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-09-08
EP2253645A2 (en) 2010-11-24
EP1587832A1 (en) 2005-10-26
US7041635B2 (en) 2006-05-09
KR100642293B1 (ko) 2006-11-03
DK2253645T3 (en) 2016-06-27
ES2446041T3 (es) 2014-03-06
LUC00023I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-09-08
KR20050044776A (ko) 2005-05-12
AU2003274766B2 (en) 2009-02-12
EP2253645A3 (en) 2011-02-16
CN100404552C (zh) 2008-07-23
LUC00023I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-21
US20040147436A1 (en) 2004-07-29
CN1745100A (zh) 2006-03-08
EP1587832B1 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
CA2514646C (en) Factor viii polypeptide
EP0939767B1 (en) Porcine factor viii and hybrids thereof
Dwarki et al. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice.
EP0672138B1 (en) Chimeric procoagulant proteins
US6458563B1 (en) Modified factor VIII
EP1200105B1 (en) Modified factor viii
US20050123997A1 (en) Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7560107B2 (en) Modified factor VIII
US8802620B2 (en) Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A
AU2001238416A1 (en) Modified factor VIII
JP2000511407A (ja) 不活性化耐性第▲viii▼因子
AU2995699A (en) Modified factor viii
WO2003087355A1 (en) Inactivation resistant factor viii
AU2002364509A1 (en) Factor viii c2 domain variants
HK1150840B (en) Factor viii polypeptide

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20231027